• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ:RVNC)

3.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.650
Bid (Size) 3.650 (47)
Ask (Size) 3.660 (542)
Prev. Close 3.650
Today's Range 3.650 - 3.650
52wk Range 3.615 - 3.670
Shares Outstanding 71,829,718
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
September 09, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 06, 2025
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
+0.3%
+0.3%

More News

Read More
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, IIPR, FTAI, and Revance and Encourages Investors to Contact the Firm
March 03, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
RVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNC
March 03, 2025
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
March 01, 2025
Via NewMediaWire
Topics Lawsuit
News headline image
SHAREHOLDER ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
March 01, 2025
Via TheNewswire.com
Topics Lawsuit
News headline image
Rosen Law Firm Urges Revance Therapeutics, Inc. (NASDAQ: RVNC) Stockholders to Contact the Firm for Information About Their Rights
February 28, 2025
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
February 28, 2025
Via NewMediaWire
Topics Lawsuit
News headline image
INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
February 28, 2025
Via TheNewswire.com
Topics Lawsuit
News headline image
RVNC DEADLINE ALERT: Kirby McInerney LLP Alerts Revance Therapeutics, Inc. Investors of Important Lead Plaintiff Deadline in Class Action Lawsuit
February 27, 2025
From Kirby McInerney LLP
Via Business Wire
News headline image
Lead Plaintiff Deadline is March 4, 2025 for Investors of Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox
February 27, 2025
Via NewMediaWire
Topics Lawsuit
News headline image
Lead Plaintiff Deadline is March 4, 2025 for Investors of Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox
February 27, 2025
Via TheNewswire.com
Topics Lawsuit
News headline image
Kaplan Fox Alerts Investors of Revance Therapeutics to the Lead Plaintiff Deadline on March 4, 2025
February 26, 2025
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Alerts Investors of Revance Therapeutics to the Lead Plaintiff Deadline on March 4, 2025
February 26, 2025
Via TheNewswire.com
Topics Lawsuit
News headline image
Securities Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox Before Deadline on March 4, 2025
February 25, 2025
Via NewMediaWire
Topics Lawsuit
News headline image
Securities Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox Before Deadline on March 4, 2025
February 25, 2025
Via TheNewswire.com
Topics Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, Nextracker, FTAI, and Revance and Encourages Investors to Contact the Firm
February 24, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Revance Therapeutics, Inc. Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm for More Information
February 19, 2025
From Johnson Fistel, LLP
Via Business Wire
News headline image
RVNC STOCK NEWS: Robbins LLP Reminds Revance Therapeutics, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025
February 18, 2025
From Robbins LLP
Via GlobeNewswire
News headline image
RVNC DEADLINE ALERT: Revance Therapeutics Investors Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on March 4, 2025
February 17, 2025
Via NewMediaWire
Topics Lawsuit
News headline image
RVNC DEADLINE ALERT: Revance Therapeutics Investors Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on March 4, 2025
February 17, 2025
Via TheNewswire.com
Topics Lawsuit
News headline image
REVANCE THERAPEUTICS INVESTOR ALERT: Kaplan Fox Alerts Investors of a Class Action Deadline on March 4, 2025
February 15, 2025
Via NewMediaWire
Topics Lawsuit
News headline image
REVANCE THERAPEUTICS INVESTOR ALERT: Kaplan Fox Alerts Investors of a Class Action Deadline on March 4, 2025
February 15, 2025
Via TheNewswire.com
Topics Lawsuit
News headline image
RVNC SHAREHOLDER ALERT: Deadline to Lead in Securities Fraud Lawsuit Against Revance Therapeutics, Inc. (RVNC) is March 4, 2025 - Contact Kaplan Fox
February 14, 2025
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
RVNC SHAREHOLDER ALERT: Deadline to Lead in Securities Fraud Lawsuit Against Revance Therapeutics, Inc. (RVNC) is March 4, 2025 - Contact Kaplan Fox
February 14, 2025
Via NewMediaWire
Topics Fraud Lawsuit

Frequently Asked Questions

Is Revance Therapeutics, Inc. - Common Stock publicly traded?
Yes, Revance Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Revance Therapeutics, Inc. - Common Stock trade on?
Revance Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Revance Therapeutics, Inc. - Common Stock?
The ticker symbol for Revance Therapeutics, Inc. - Common Stock is RVNC on the Nasdaq Stock Market
What is the current price of Revance Therapeutics, Inc. - Common Stock?
The current price of Revance Therapeutics, Inc. - Common Stock is 3.650
When was Revance Therapeutics, Inc. - Common Stock last traded?
The last trade of Revance Therapeutics, Inc. - Common Stock was at 02/05/25 04:00 PM ET
What is the market capitalization of Revance Therapeutics, Inc. - Common Stock?
The market capitalization of Revance Therapeutics, Inc. - Common Stock is 262.18M
How many shares of Revance Therapeutics, Inc. - Common Stock are outstanding?
Revance Therapeutics, Inc. - Common Stock has 262M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap